Page last updated: 2024-12-07

inositol 1,4-bis(phosphate)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

inositol 1,4-bis(phosphate): induced in human platelets by thrombin; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1D-myo-inositol 1,4-bisphosphate(4-) : An organophosphate oxoanion arising from deprotonation of the phosphate OH groups of 1D-myo-inositol 1,4-bisphosphate; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID25203530
CHEBI ID58282
MeSH IDM0129420

Synonyms (16)

Synonym
1d-myo-inositol 1,4-bisphosphate(4-)
1d-myo-inositol 1,4-bis(phosphate)
1d-myo-inositol 1,4-bisphosphate tetraanion
CHEBI:58282
i(1,4)p2
myo-inositol (1,4)-bisphosphate
inositol (1,4)-bisphosphate
d-myo-inositol (1,4)-bisphosphate
inositol 1,4-bis(phosphate)
1,4,-ip2
gtpl5098
[(2r,3s,5r,6r)-2,3,5,6-tetrahydroxy-4-phosphonatooxycyclohexyl] phosphate
Q28529707
Q27070774
PD047553
[(2r,3r,5r,6s)-2,3,5,6-tetrahydroxy-4-phosphonatooxycyclohexyl] phosphate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (2)

PathwayProteinsCompounds
D-myo-inositol (1,4,5)-trisphosphate degradation56
D-myo-inositol (1,4,5)-trisphosphate degradation147
superpathway of D-myo-inositol (1,4,5)-trisphosphate metabolism2015

Research

Studies (60)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (50.00)18.7374
1990's26 (43.33)18.2507
2000's2 (3.33)29.6817
2010's2 (3.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]